Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing?
Syria Laperche(Établissement Français du Sang), Y. Piquet(Société de Réanimation de Langue Française), Annabelle Servant‐Delmas(Institut National de la Transfusion Sanguine), Marianne Asso‐Bonnet(Hôpital Foch), Pascal Morel, Marie Deschaseaux(Établissement Français du Sang), Marie‐Hélène Elghouzzi(Société de Réanimation de Langue Française), A Girault(Institut National de la Transfusion Sanguine), Nadine Le Marrec(Institut National de la Transfusion Sanguine), Françoise Bouchardeau(Institut National de la Transfusion Sanguine)
Cited by 55
Related Papers
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
|Science Immunology|2021|638
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
|Proceedings of the National Academy of Sciences|2022|198
Simultaneous Detection of Hepatitis C Virus (HCV) Core Antigen and Anti-HCV Antibodies Improves the Early Detection of HCV Infection
|Journal of Clinical Microbiology|2005|115
Sensitivities of Four New Commercial Hepatitis B Virus Surface Antigen (HBsAg) Assays in Detection of HBsAg Mutant Forms
|Journal of Clinical Microbiology|2006|92